Glipizide and Metformin HCl
Brand Names: Glipizide and Metformin HCl Generic
Methodology & AI Transparency ⓘ
Glipizide and Metformin HCl Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: Glipizide and Metformin HCl Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- 2 Real-world patient consensus: Tracked across 18 patient dosage logs with a 92% satisfaction benchmark (RxCUI 861740).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $16.23 cash mean against $39.76 retail pharmacy pricing.
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Glipizide and Metformin HCl: nausea (7.4%), headache (6.5%), dizziness (5.9%).
Ask our AI Specialists anything about Glipizide and Metformin HCl
Glipizide and Metformin HCl Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: Glipizide and Metformin HCl Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
CLINICAL PHARMACOLOGY Mechanism of Action Glipizide and Metformin HCl Tablets combines glipizide and metformin hydrochloride, 2 antihyperglycemic agents with complementary mechanisms of action, to improve glycemic control in patients with type 2 diabetes. Glipizide appears to lower blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. Extrapancreatic effects may play a part in the mechanism of action of oral sulfonylurea hypoglycemic drugs.
Pharmacokinetic profiling of Glipizide and Metformin HCl demonstrates an elimination half-life of Approximately 6–15 hours terminal plasma half-life for Glipizide and Metformin HCl with Estimated 70%–82% oral systemic absorption for Glipizide and Metformin HCl systemic bioavailability; clearance proceeds via phase i/ii hepatic conjugation of glipizide and metformin hcl coupled with glomerular and tubular renal excretion, reaching clinical onset within peak plasma concentration (tmax) reached 1–4 hours post-dose for glipizide and metformin hcl.
Titration schedules for Glipizide and Metformin HCl (5 mg/1 / 500 mg/1 Tablet, Film Coated → 2.5 mg/1 / 500 mg/1 Tablet, Film Coated → 2.5 mg/1 / 250 mg/1 Tablet, Film Coated) require excluding contraindications glipizide and metformin hcl tablets are contraindicated in patients with: 1.; severe renal impairment (egfr below 30 ml/min/1.73 m 2 ).; known hypersensitivity to glipizide or metformin hydrochloride.; real-world patient logs highlight nausea (7.4% of reports), headache (6.5% of reports), dizziness (5.9% of reports) alongside a 92.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Glipizide and Metformin HCl (sulfonylurea).
Unstandardized herbal extracts may interact pharmacodynamically with Glipizide and Metformin HCl maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS Glipizide and Metformin HCl Tablets are contraindicated in patients with: 1.
- Severe renal impairment (eGFR below 30 mL/min/1.73 m 2 ).
- Known hypersensitivity to glipizide or metformin hydrochloride.
Logged Side-Effect Incidence (18 Reports)
Glipizide and Metformin HCl Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Glipizide and Metformin HCl)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes: What a 406-Participant Study Found Despite similar 52-week glycemic efficacy, dapagliflozin reduced weight and produced less low blood sugar than glipizide in type 2 diabetes inadequately controlled with metformin. Diabetes care • 2011-09-15 • Randomized Controlled Trial | N = 406 | 93/100 | PMID 21816980 ↗ |
| Can This Approach Help? Inside the Latest Research on One year comparative trial of metformin and glipizide in type 2 Both drugs caused a similar reduction in albumin excretion rates. Diabete & metabolisme • 1994-01-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 7843470 ↗ |
Glipizide and Metformin HCl Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1910/unit (~$5.73/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $39.76 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $16.23 / mo | View logs ↓ |
Glipizide and Metformin HCl Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Glipizide and Metformin HCl RxNorm Concept ID | 861740 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1910 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $39.76 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $16.23 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 92.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Glipizide and Metformin HCl Patient Community, Cohort Filters & Dosage Logs
Cross-verified Glipizide and Metformin HCl (sulfonylurea) monograph synthesizing RxNorm 861740, openFDA FAERS signals, and $16.23–$39.76 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Glipizide and Metformin HCl community threads and patient logs by age, biological sex, dosage, and treatment duration.